Buccal spray insulin (Oralgen) for type 2 diabetes: what evidence?

Bibliography

• International Diabetes Federation Guideline Development Committee. Guideline for Management of Postmeal Glucose. International Diabetes Federation; Brussels, Belgium: 2007
   Google Scholar
• Pozzilli P, Leslie RD, Chan J, The A1C and ABCD of glycemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev 2010;26:239-44
   PubMed Web of Science ®Google Scholar
• Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 1997;20:292-8
   PubMed Web of Science ®Google Scholar
• Royle P, Waugh N, McAuley L, Inhaled insulin in diabetes mellitus. Cochrane Database Syst Rev 2004;3:CD003890
   PubMedGoogle Scholar
• Heinemann L. New ways of insulin delivery. Int J Clin Pract Suppl 2010;(166):41-6
   PubMedGoogle Scholar
• Bernstein G. Delivery of insulin to the buccal mucosa utilizing the RapidMist system. Expert Opin Drug Deliv 2008 Sep;5(9):1047-55
   PubMed Web of Science ®Google Scholar
• Generex Biotechnology Corp. Data on File. 2008
   Google Scholar
• Cernea S, Kidron M, Wohlgelernter J, Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. Clin Ther 2004;26:2084-209
   PubMed Web of Science ®Google Scholar
• Cernea S, Kidron M, Wohlgelerenter J, Dose-response relationship of oral insulin spray in healthy subjects. Diabetes Care 2005;28:1353-7
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Manfrini S, Costanza F, Biokinetics of buccal spray insulin in patients with type 1 diabetes. Metabolism 2005;54:930-4
   PubMed Web of Science ®Google Scholar
• Cernea S, Kidron M, Wohlgelernter J, Dose–response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. Clin Ther 2005;27:1562-70
   PubMed Web of Science ®Google Scholar
• Lutz H, Yves J. Oral Insulin and buccal insulin: a critical reappraisal. J Diabetes Sci Technol 2009;3:568-84
   PubMedGoogle Scholar
• Guevara-Aguirre J, Guevara M, Saavedra J, Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents. Diabetes Technol Ther 2004;6:1-8
   PubMedGoogle Scholar
• Guevara-Aguirre J, Guevara M, Saavedra J, Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study. Diabetes Metab Res Rev 2004;20:472-8
   PubMed Web of Science ®Google Scholar
• Palermo A, Napoli N, Manfrini S, Buccal spray insulin in subjects with impaired glucose tolerance: the prevoral study. Diabetes Obes Metab 2011;13:42-6
   PubMed Web of Science ®Google Scholar
• Bernstein G. Delivery of insulin to the buccal mucosa utilizing the RapidMist system. Expert Opin Drug Deliv 2008;5:1047-55
   PubMed Web of Science ®Google Scholar
• Palermo A, Napoli N, Maddaloni E, Buccal spray insulin for the treatment of impaired glucose tolerance. IDF 2011; DU-0374
   Google Scholar
• Tuomilento J, Lindstrom J, Eriksson JG, Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50
   PubMed Web of Science ®Google Scholar
• Zambanini A, Feher MD. Needle phobia in type 1 diabetes mellitus. Diabet Med 1997;14:321-3
   PubMed Web of Science ®Google Scholar
• Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26(Suppl 3):S18-24
   PubMed Web of Science ®Google Scholar
• Okazaki K, Goto M, Yamamoto T, Barriers and facilitators in relation to starting insulin therapy in type 2 diabetes. Diabetes 2008;48(Suppl):A1394
   Google Scholar
• Polonsky WH, Fisher L, Guzman S, Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543-5
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, STOP-NIDDM Trail Research Group. Acarbose for prevention of DM2: STOP-NIDDM randomised trial. Lancet 2002;359:2072-7
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Yusuf S, Bosch J, DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of Rosiglitazone on frequency of DM in IGT or IFG The dream trial investigators. Lancet 2006;368:1096-105
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Tripathy D, Schwenke DC, ACT NOW Study. Pioglitazone for Diabetes prevention in IGT. N Engl J Med 2011;364:1104-15
   PubMed Web of Science ®Google Scholar
• Nathan DM, Davidson MB, DeFronzo RA, Impaired Fasting Glucose and Impaired Glucose Tolerance: implications for care. Diabetes Care 2007;30:753-9
   PubMed Web of Science ®Google Scholar
• Bell DS, O'Keefe JH, Jellinger P. Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? Endocr Pract 2008;14:112-24
   PubMedGoogle Scholar